BioFocus DPI AG

As the service division of Galapagos (Euronext and LSE: GLPG), BioFocus DPI offers a full suite of target-to-drug discovery products and services.

Our aim is to expand our partners’ drug pipeline by accelerating the gene-to-candidate discovery process. We achieve this by offering a biologically-focused discovery platform with three key differentiators - target discovery in human primary cells; focused as well as diverse compound libraries; and predictive drug discovery tools.

Through full-length cDNA and shRNA constructs, we are able to identify and validate disease-modifying drug targets rapidly. Once a target has been selected, our focused small-molecule, large diversity collection and natural product libraries can be applied to generate “hits”. These hits can then be further optimized through our expertise in medicinal and computational chemistry as well as through our assay development, high throughput screening, and ADME optimization - thereby progressing our partners’ discovery programs.